Organogenesis director receives 48,828 stock units

Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an equity award of Class A common stock.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an equity award of Class A common stock. He acquired 48,828 shares through a grant of restricted stock units (RSUs) at no cash cost, increasing his directly held stake to 286,014 shares after the transaction.

The RSUs were granted under the Organogenesis 2018 Equity Incentive Plan. Each RSU converts into one share of Class A common stock upon vesting, and the entire award is scheduled to vest in full on February 15, 2027, aligning director compensation with the company’s long-term performance.

Insider Trade Summary

Grant/Award: 48,828 shares

Grant/Award 1 txn

Insider Leibowitz Arthur S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	48,828	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 286,014 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Arthur S. Leibowitz report in this Organogenesis (ORGO) Form 4 filing?

Arthur S. Leibowitz reported an equity award of Organogenesis Class A common stock. He received 48,828 shares via restricted stock units, raising his direct holdings to 286,014 shares after the transaction, reflecting stock-based director compensation rather than an open-market purchase.

How many Organogenesis (ORGO) shares were granted to the director in this transaction?

The director was granted 48,828 restricted stock units representing Class A common stock. Each unit corresponds to one share upon vesting, meaning the award covers 48,828 future shares tied to continued service and vesting conditions rather than an immediate cash purchase.

When do the awarded Organogenesis (ORGO) RSUs to Arthur S. Leibowitz vest?

The restricted stock units granted to Arthur S. Leibowitz vest in full on February 15, 2027. On that vesting date, each RSU is scheduled to convert into one share of Organogenesis Class A common stock, assuming the vesting requirements are satisfied through that time.

What is Arthur S. Leibowitz’s Organogenesis (ORGO) share ownership after this Form 4 transaction?

Following the equity award, Arthur S. Leibowitz directly holds 286,014 shares of Organogenesis Class A common stock. This total reflects his position after the grant of 48,828 restricted stock units, as reported in the Form 4 insider ownership disclosure.

Was there any cash paid for the Organogenesis (ORGO) shares reported in this Form 4?

No cash consideration was reported for the shares in this Form 4. The 48,828 shares were acquired through a grant of restricted stock units at a price per share of $0.0000, indicating a stock-based compensation award rather than an open-market purchase.

Under which plan were the Organogenesis (ORGO) RSUs to Arthur S. Leibowitz granted?

The restricted stock units were granted under the Organogenesis Holdings Inc. 2018 Equity Incentive Plan. This plan provides equity-based awards, and in this case each RSU represents the contingent right to receive one share of Class A common stock upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leibowitz Arthur S

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A(1)		48,828	A	$0	286,014	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.